oral glp-1 drugs in development What is the pipeline for future medications for obesity? Scam weight-loss drops marketed to

Description

While the research base for microdosing, specifically, is still developing, and lower-dose protocols are being explored, though clinical evidence for efficacy at sub-therapeutic doses remains limited

Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats

More promising results, however, were announced the same month by Eli Lilly for its new once-daily GLP-1 pill which showed promise for weight management and for the treatment of type-2 diabetes

I believe that NLRP3 , NR3C1, Amylin, Apelin, Activin and many other targets we described in our prior publications are poised to complement the effects of GLP-1, creating comprehensive anti-aging regimens